Kindred Biosciences, Inc.
(NASDAQ : KIN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.60%163.540.7%$1305.95m
LLYEli Lilly & Co. -1.93%323.651.1%$1056.02m
ABBVAbbVie, Inc. -5.84%134.381.9%$793.06m
PFEPfizer Inc. -0.75%43.830.9%$778.51m
BMYBristol-Myers Squibb Co. -0.82%71.121.0%$763.08m
MRKMerck & Co., Inc. -0.52%86.190.7%$687.90m
AZNAstraZeneca Plc -0.13%54.841.0%$411.81m
NVSNovartis AG -0.73%76.010.2%$216.26m
GSKGSK Plc 0.31%29.450.3%$214.53m
ALNYAlnylam Pharmaceuticals, Inc. -4.41%200.168.2%$210.64m
GBTGlobal Blood Therapeutics, Inc. 0.04%68.105.4%$190.73m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.21%151.220.0%$178.64m
IDXXIDEXX Laboratories, Inc. -1.81%325.803.9%$175.84m
HZNPHorizon Therapeutics Plc -1.28%61.895.4%$160.55m
NVONovo Nordisk A/S -0.74%99.650.1%$140.44m

Company Profile

Kindred Biosciences is a veterinary biotechnology company, focuses on developing therapies for dogs, cats, and horses. It develops canine, feline, and equine antibodies for the treatment of diseases in companion animals. Its strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for animal companions. Their mission is to bring innovative biologics to veterinary medicine because they believe their pets deserve the same kinds of safe and effective medicines that human family members enjoy. The company was incorporated in 2012 and is based in San Francisco, California.